ZA200108610B - Medicaments contining inhibitors of cell-volume regulated human kinase h-sgk. - Google Patents

Medicaments contining inhibitors of cell-volume regulated human kinase h-sgk. Download PDF

Info

Publication number
ZA200108610B
ZA200108610B ZA200108610A ZA200108610A ZA200108610B ZA 200108610 B ZA200108610 B ZA 200108610B ZA 200108610 A ZA200108610 A ZA 200108610A ZA 200108610 A ZA200108610 A ZA 200108610A ZA 200108610 B ZA200108610 B ZA 200108610B
Authority
ZA
South Africa
Prior art keywords
inhibitor
sgk
hsgk
medicament
human cell
Prior art date
Application number
ZA200108610A
Inventor
Siegfried Waldegger
Carsten Wagner
Stefan Broeer
Karin Klingel
Original Assignee
Lang Florian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lang Florian filed Critical Lang Florian
Publication of ZA200108610B publication Critical patent/ZA200108610B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

as originally filed
Medicaments comprising inhibitors of the cell volume-regulated human kinase h-sgk -—
The present invention relates to medicaments comprising inhibitors or activators of the cell volume-regulated human kinase h-sgk. Such pharmaceuticals are suitable for the therapy of pathological states in which an increased or reduced expression of h-sgk is found. EP-0 861 896 has already described h-sgk and processes for its preparation, and the contents thereof are expressly intended also to form part of the present description.
Definitions of terms: h-sgk: human serum and glucocorticoid dependent kinase (serine/threonine kinase)
ENaC: epithelial Na* channel
MDEG: mammalian degenerin (Waldmann, R., Lazdunski, M. (1998) Current
Opinion in Neurobiology 8: 418-424); a synonymous term is “BNC” (brain Na* channel)
TGFB;: tumor growth factor f
NKCC: Na’, K',2CI cotransporter
HEPES: [4-(2-hydroxyethyl)piperazino]ethanesulfonic acid
SEM: standard error of mean
Trans- dominant inhibitory kinase: h-sgk modified by mutation: lysine in position 127 has been replaced by arginine (K127R); thc mutation is located in the catalytic region and suppresses the catalytic function of the kinase.
An increased expression of h-sgk is often found in diabetes mellitus, arteriosclerosis, Alzheimer’s disease, cirrhosis of the liver, Crohn’s disease, fibrosing pancreatitis, pulmonary fibrosis and chronic bronchitis. The increased production of h-sgk can be explained by stimulation of expression by TGFB,
o" (fig. 1). Fibrotic disorders are caused by increased formation and reduced breakdown of matrix proteins. Both are effects of TGF. Increased expression of the matrix proteins in fibroblasts can be suppressed by inhibiting the NKCC with furosemide (fig. 2). It has to date been unclear whether the increased expression of h-sgk is only a consequence or is the cause of the disorder.
Surprising findings now prove h-sgk activates Na*, K*, 2Cl cotransport (fig. 3). It can be concluded from this that stimulation of NKCC by h-sgk induces fibrosis.
Besides Na®, K*, 2CI" cotransport, h-sgk also activates ENaC (figs. 4 and 5) and
MDEG.
The stimulating effect of h-sgk on ENaC can be suppressed by kinase inhibitors such as, for example, staurosporine (Sigma, D-82041 Deisenhofen) or chelerythrine (Sigma, loc. cit.) (fig. 4). In addition, the effect of h-sgk on ENaC can be suppressed, for example, by trans-dominant inhibitory kinase (fig. 5). Inhibitors of h-sgk such as staurosporine, chelerythrine or other kinase inhibitors might therefore be employed in the therapy of the abovementioned disorders. Generally suitable for this purpose are all known kinase inhibitors. Kinase inhibitors are also commercially available in many cases, for example from Calbiochem-
Novabiochem GmbH, Listweg 1, D-65812 Bad Soden (see “1998 General
Catalog”). Further kinase inhibitors can be obtained from other commercial and noncommercial sources known to the skilled worker.
Expression of h-sgk is increased in an epileptic seizure. The functional data we 75 have found show that the effects are suitable for reducing the excitability of neurons because activation of NKCC leads to a reduction in the extracellular K* concentration, which is followed by hyperpolarization and thus inhibition of the activity of neurons. In addition, the inhibition of MDEG ought to inhibit neuronal excitability. Accordingly, kinase activators which cross the blood-brain barrier might be employed successfully for epileptic seizures. Conversely, kinase inhibition with drugs crossing the blood-brain barrier might increase attentiveness and learning ability. Kinase activators have moreover been known to the skilled worker for a lengthy period, among which the protein kinase C activators are particularly of interest (see, for example, Calbiochem-Novabiochem 1998 General
Catalog, loc. cit.). Further kinase activators can be obtained from other commercial and noncommercial sources known to the skilled worker.
Since the Na®, K*, 2CI" cotransport and the Na* channel are crucial for renal Na’ absorption and an increased renal Na" absorption is associated with hypertension, it must be assumed that increased expression of the kinase leads to hypertension and reduced expression of the kinase leads to hypotension.
The present invention thus also relates to the use of inhibitors of h-sgk for producing medicaments for the treatment of diabetes mellitus, arteriosclerosis,
Alzheimer’s disease, cirrhosis of the liver, Crohn’s disease, fibrosing pancreatitis, pulmonary fibrosis, chronic bronchitis, radiation fibrosis, scleroderma, cystic fibrosis and other fibrosing disorders, and for the therapy of essential hypertension.
Medicaments comprising inhibitors or activators of h-sgk can additionally be employed to regulate neuronal excitability. It is particularly advantageous to use the inhibitors staurosporine or chelerythrine and their analogs.
RESULTS
Diabetic kidney:
Expression of h-sgk in the normal kidney is only low. A few cells in the glomerulus, late proximal and distal tubule show distinct h-sgk expression. In contrast to this, cells with massive h-sgk expression accumulate in the diabetic kidney.
Arteriosclerosis:
Cells massively expressing h-sgk are frequently found in the walls of arteriosclerotic vessels.
Alzheimer’s disease:
Only a few cells expressing h-sgk are found in the normal brain. These cells are probably oligodendroglial cells. The number of h-sgk-expressing cells is significantly increased in brains with Alzheimer’s disease.
Cirrhosis of the liver:
Only copper cells express h-sgk in the normal liver. However, in cirrhosis of the liver the tissue is dotted with h-sgk-expressing cells.
Crohn’s disease:
In normal intestinal tissue, h-sgk is expressed exclusively in the enterocytes.
: te
However, in Crohn’s disease, the kinase is also found in connective tissue.
Fibrosing pancreatitis:
In the normal pancreas, h-sgk is found in acinar cells and in duct cells. A few h-sgk-expressing mononuclear cells are found around the pancreatic ducts. There is a marked increase in kinase expression in fibrosing pancreatitis.
Pulmonary fibrosis and chronic bronchitis:
Massive expression of h-sgk is observed in pulmonary fibrosis and chronic bronchitis.
Stimulation of h-sgk expression by TGF8;: : The expression of h-sgk is stimulated by TGF8, (fig. 1). Since TGFB; is produced in fibrotic/inflamed tissue, this finding explains the increased expression of h-sgk in inflamed tissue.
TGFB, stimulates the expression of the matrix protein biglycan, an effect which is suppressed by the NKCC inhibitor furosemide:
TGFB, stimulates the expression of biglycan. In the presence of the NKCC inhibitor furosemide, the effect of TGFB; on biglycan expression is completely suppressed. Thus activation of NKCC is a precondition for the fibrotic effect of
TGFB, . (fig. 2).
Stimulation of NKCC by h-sgk:
The significance of the increased expression of the kinase in fibrotic tissue might be manifold and not causally connected with the fibrosis. However, experiments with the two-electrode voltage clamp have shown that the activity of NKCC is massively stimulated by h-sgk (fig. 3). In view of the furosemide sensitivity of biglycan synthesis, this finding unambiguously demonstrates a causal role of h-sgk in fibrosis.
Stimulation of ENaC by h-sgk:
This effect can be suppressed by the kinase inhibitors staurosporine and chelerythrine. As fig. 4 shows, there is a massive increase in the current with ENaC through coexpression with h-sgk. The kinase therefore stimulates ENaC. The kinase inhibitors staurosporine and chelerythrine are able completely to suppress
. the activation of ENaC by h-sgk.
Stimulation of epithelial ENaC by h-sgk can be reversed by coexpression of the trans-dominant inhibitory kinase h-sgk: 5S As fig. 5 shows, the stimulating effect of h-sgk coexpression on the ENaC- mediated Na* current can be suppressed by coexpression of a trans-dominant inhibitory kinase. This trans-dominant inhibitory kinase (compare with “definitions of terms”) is modified on the catalytic unit in such a way that it can no longer display its function. However, since it binds to the substrate it displaces the active kinase and thus suppresses its effects. The trans-dominant inhibitory kinase not only suppresses the increase in ENaC activity due to exogenous h-sgk but evidently also suppresses the stimulation by endogenous h-sgk.
MDEG is completely blocked by coexpression with h-sgk:
As fig. 6 shows, expression of MDEG in oocytes induces a strong Na“ current which is activated by lowering the extracellular pH. The channel is completely blocked by coexpression with h-sgk. It must be concluded from this that h-sgk inhibits neuronal excitability. Examples:
Example 1: In situ hybridization
Tissue from normal pancreas, liver, vessels, brain, lung, kidney and intestine, and tissue with diabetic nephropathy, arteriosclerosis, Alzheimer’s disease, cirrhosis of the liver, Crohn’s disease, fibrosing pancreatitis and pulmonary fibrosis was embedded in paraffin in 4% paraformaldehyde/0.1 M sodium phosphate buffer (pH 7.2) for 4 hours. Tissue sections were dewaxed and hybridized as described previously (Kandolf, R., D. Ameis, P. Kirschner, A. Canu, P.H. Hofschneider,
Proc. Natl. Acad. Sci. USA 84: 6272-6276, 1987; Hohenadl, C., K. Klingel, J.
Mertsching, P. H. Hofschneider, R. Kandolf., Mol. Cell. Probes 5: 11-20, 1991;
Klingel, K., C. Hohenadl, A. Canu, M. Albrecht, M. Seemann, G. Mall, R.
Kandolf, Proc. Nail. Acad. Sci. USA, 89: 314-318, 1992).
The hybridization mixture contained either 35S.labeled sense RNA coding for h- sgk or *’S-labeled antisense RNA complementary to the latter RNA (500 ng/ml of each) in 10 mM Tris-HCI, pH 7.4; 50% (vol/vol) deionized formamide; 600 mM
NaCl; 1 mM EDTA; 0.2% polyvinylpyrrolidone; 0.02% Ficoll; 0.05% calf serum albumin; 10% dextran sulfate; 10 mM dithiothreitol; 200 pg/ml denatured of sonicated salmon sperm DNA and 100 pg/ml rabbit liver tRNA. a
Hybridization with RNA probes was carried out at 42°C for 18 hours. The slides were washed as described (Hohenadl et al., 1991; Klingel et al., 1992), and then incubated in 2x standard sodium citrate at 55°C for 1 hour. Unhybridized single- stranded RNA probes were digested by RNase A (20 pg/ml) in 10 mM Tris-HCl, pH 8.0/0.5M NaCl at 37°C for 30 min. Tissue samples were then autoradiographed for three weeks (Klingel et al, 1992) and stained with hematoxylin/eosin.
Example 2: Transcriptional regulation of biglycan and h-sgk
Cells were cultivated in RPMI/5% CO,/10 mM glucose at 37°C, pH 74, supplemented with 10% (vol/vol) fetal calf serum (FCS). The cells were grown to 90% confluence and then homogenized in TRIZOL (GIBCO/BRL) (about 0.4x10° per sample). Total RNA was prepared in accordance with the manufacturer’s instructions. Northern blots were fractionated by electrophoresis through 10 g/l agarose gels with 15 or 20 ug of total RNA with separate control in the presence of 2.4 mol/l formaldehyde. RNA was transferred by vacuum (Appligene Oncor Trans
DNA Express Vacuum Blotter, Appligine, Heidelberg, Germany) to positively charged nylon membranes (Boehringer Mannheim, Germany) and crosslinked under ultraviolet light (UV Stratalinker 2400, Stratagene, Heidelberg, Germany).
Hybridization was carried out over night with DIG-Easy-Hyb (Boehringer
Mannheim) at a probe concentration of 25 pg/l at 50°C. The digoxigenin (DIG)- labeled probes were produced by PCR as described in detail earlier (Waldegger et al. (1997) PNAS 94: 4440-4445). For the autoradiography, the filters were exposed to an X-ray film (Kodak) for an average of 5 min.
Example 3: Two-electrode voltage clamp and tracer flux experiments
Dissection of Xenopus laevis, and the obtaining and treatment of the oocytes has been described in detail earlier (Busch et al. 1992). The oocytes were each injected with 1 ng of cRNA of NKCC, ENaC or MDEG with or without simultaneous injection of h-sgk. It was possible to carry out two-electrode voltage and current clamp experiments 2-8 days after the injection. Na' influx which could be inhibited by furosemide through the NKCC was measured by the Na" uptake, which was determined with a scintillation counter, into the oocytes. Na’ currents (ENaC) were filtered at 10 Hz and recorded with a pen recorder. The experiments were normally , carried out on the second day after cRNA injection. The bath solution contained: 96 mM NaCl, 2 mM KCl, 1.8 mM CaCl,, 1 mM MgCl, and 5 mM HEPES at pH 7.5 and the holding potential was -50 mV. The pH was adjusted by titration with HCI or NaOH in all the experiments. The flow rate of the bath liquid was set at 20 ml/min, which ensured a complete change of solution in the measurement chamber within 10-15 s. All the data are stated in the form of arithmetic means +
SEM.
Figure legends:
Fig. 1: Stimulation of h-sgk expression by TGFf;: ! The expression of h-sgk is stimulated by TGFB;. The effect of TGF, after 0.5 to 6 h is shown (top). The phorbol ester PDD (4-alpha-phorbol 12,13-didecanoate; stimulates protein kinase C) and the Ca" ionophore jonomycin (Sigma, loc. cit; increases the intracellular Ca™ concentration) likewise stimulate h-sgk expression (below).
Fig. 2: Stimulation of biglycan expression by TGF8;:
The expression of biglycan (B) is stimulated by osmotic swelling of cells (hypo = h, top left) and by TGFB; (top right). The effect of TGFB; on biglycan expression is almost completely suppressed in the presence of the
NKCC inhibitor bumetanide (b) (control = c).
Fig. 3: Stimulation of the NKCC by h-sgk:
The uptake which can be inhibited by furosemide of 22Na* in oocytes [uptake (nmol/20 min/oocyte) = u] which express the NKCC is massively stimulated by h-sgk. NKCC-injected oocytes do not show a higher Na' influx than uninjected oocytes (n.i.). This Na" influx is not inhibited by the
NKCC inhibitor furosemide (= F) (top). Expression of h-sgk alone does not lead to stimulation of the Na’ influx. Cocxpression of h-sgk with NKCC leads to a large increase in the Na’ influx, and this increase is completely suppressed by furosemide (below).
Fig. 4: Stimulation of the ENaC by h-sgk:
The current through the ENaC (I) increases massively through coexpression with h-sgk. Treatment of the oocytes with the Kinase inhibitors
AMENDED SHEET i ® 8 staurosporine (S) or chelerythrine (C) suppresses the activation of the Na channel by h-sgk.
Fig. 5: The stimulation of the ENaC by h-sgk can be reversed by coexpression of the trans-dominant inhibitory kinase: oocytes expressing ENaC and h-sgk simultaneously show very much larger currents (I) than do oocytes expressing only ENaC. Coexpression of the trans-dominant inhibitory kinase suppresses the stimulation of the ENaC by h-sgk.
Fig. 6: Inhibition of the MDEG by h-sgk:
The current through the MDEG (I) increases with the duration of the incubation [day (T) 1-4]. The current is completely suppressed by coexpression with h-sgk (peak = p; plateau = pl). "Comprises/comprising" when used in this specification is taken to specify the presence of stated features, integers, steps or components but does not preclude the presence or addition of one or more other features, integers, steps or components or groups thereof.

Claims (1)

  1. AMENDED SHEET EP0003578
    1. A medicament comprising an inhibitor of the human cell volume-regulated kinase hsgk for the therapy of hypertension with suppression of the stimulating effect of hsgk on the epithelial sodium channel (ENaC).
    2. A medicament as claimed in claim 1, which comprises chelerythrine as inhibitor.
    3. A medicament comprising an inhibitor of the human cell volume-regulated kinase hsgk for the therapy of at least one of the disorders from the group of cirrhosis of the liver, fibrosing pancreatitis, pulmonary fibrosis, radiation fibrosis, scleroderma, cystic fibrosis and chronic bronchitis with suppression of the stimulation of hsgk on the epithelial sodium channel (ENaC) and/or of the Na*, K, 2 CI cotransporter (NKCC). 4, A medicament as claimed in claim 3, which comprises staurosporine or chelerythrine as inhibitor.
    5S. A medicament comprising an activator of the human cell volume-regulated kinase hsgk for the treatment of epilepsy with stimulation of the Na’, K', 2 CI” cotransporter (NKCC) and/or with block of the brain-specific sodium channel MDEG. The use of an inhibitor of the human cell volume-regulated kinase hsgk for producing a medicament for the treatment of hypertension with suppression of the stimulating effect of hsgk on the epithelial sodium channel (ENaC).
    7. The use of chelerythrine as inhibitor as claimed in claim 6.
    8. The use of an inhibitor of the human cell volume-regulated kinase hsgk for producing a medicament for the treatment of at least one of the disorders from the group of cirrhosis of the liver, fibrosing pancreatitis, pulmonary fibrosis, radiation fibrosis, scleroderma, cystic fibrosis and chronic
    AMENDED SHEET EP0003578 bronchitis with suppression of the stimulation of hsgk on the epithelial sodium channel (ENaC) and/or of the Na’, K”, 2 CI” cotransporter (NKCC).
    9. The use of staurosporine or chelerythrine as inhibitor as claimed in claim 8.
    10. The use of an activator of the human cell volume-regulated kinase hsgk for producing a medicament for the treatment of epilepsy with stimulation of the Na’, K', 2 CI” cotransporter (NKCC) and/or with block of the brain-specific sodium channel (MDEG).
    11. The use of inhibitors of the epithelial sodium channel (ENaC) or of the Na’, K', 2 CI" cotransporter (NKCC) or a mixture thereof for producing a medicament for the treatment of hypertension and/or at least one of the disorders from the group of cirrhosis of the liver, fibrosing pancreatitis, pulmonary fibrosis, radiation fibrosis, scleroderma, cystic fibrosis and chronic bronchitis.
    12. The use of the quantitative detection of the human cell volume-regulated kinase hsgk for diagnosing hypertension/hypotension or at least one of the disorders from the group of fibrosing pancreatitis, radiation fibrosis, scleroderma, cystic fibrosis, chronic bronchitis and epilepsy.
    13. A kit for carrying out a quantitative detection of the human cell volume- regulated kinase hsgk as claimed in claim 12.
    14. A method for identifying inhibitors of the human cell volume-regulated kinase hsgk, in which the modulation of the activity of the epithelial sodium channel (ENaC) and/or of the brain-specific sodium channel (MDEG) and/or the modulation of the activity of the Na’, K', 2 CI’ cotransporter (NKCC) is measured.
    15. An inhibitor of the human cell volume-regulated kinase hsgk which can be identified by a method as claimed in claim 14.
    16. A medicament as claimed in any one of claims 1 to 5, substantially as hereinbefore described and exemplified.
    17. A medicament including any new and inventive integer or combination of integers, substantially as herein described.
    AMENDED SHEET EP0003578
    18. The use of an inhibitor as claimed in any one of claims 6 to 9 and 11, substantially as hereinbefore described and exemplified.
    19. The use of an inhibitor including any new and inventive integer or combination of integers, substantially as herein described.
    20. The use of an activator as claimed in claim 10, substantially as hereinbefore described and exemplified.
    21. The use of an activator including any new and inventive integer or combination of integers, substantially as herein described.
    22. The use of quantitative detection as claimed in claim 12, substantially as hereinbefore described and exemplified.
    23. The use of quantitative detection including any new and inventive integer or combination of integers, substantially as herein described.
    24. A kit as claimed in claim 13, substantially as hereinbefore described and exemplified.
    25. A kit including any new and inventive integer or combination of integers, substantially as herein described.
    26. An inhibitor as claimed in claim 15, substantially as hereinbefore described and exemplified.
    27. An inhibitor including any new and inventive integer or combination of integers, substantially as herein described.
    28. The method according to the invention for identifying inhibitors, substantially as hereinbefore described and exemplified.
    29. The method for identifying inhibitors including any new and inventive integer or combination of integers, substantially as herein described.
ZA200108610A 1999-04-20 2001-10-19 Medicaments contining inhibitors of cell-volume regulated human kinase h-sgk. ZA200108610B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19917990A DE19917990A1 (en) 1999-04-20 1999-04-20 Medicament containing inhibitors of cell volume regulated human kinase h-sgk

Publications (1)

Publication Number Publication Date
ZA200108610B true ZA200108610B (en) 2002-01-02

Family

ID=7905297

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200108610A ZA200108610B (en) 1999-04-20 2001-10-19 Medicaments contining inhibitors of cell-volume regulated human kinase h-sgk.

Country Status (18)

Country Link
EP (1) EP1171131A1 (en)
JP (1) JP2002542196A (en)
KR (1) KR100718900B1 (en)
CN (1) CN1351496A (en)
AU (1) AU779941B2 (en)
BR (1) BR0009914A (en)
CA (1) CA2369078A1 (en)
CZ (1) CZ20013778A3 (en)
DE (1) DE19917990A1 (en)
HU (1) HUP0200819A3 (en)
MX (1) MXPA01010588A (en)
NO (1) NO20015054L (en)
PL (1) PL198427B1 (en)
RU (1) RU2288718C9 (en)
SK (1) SK14972001A3 (en)
UA (1) UA79066C2 (en)
WO (1) WO2000062781A1 (en)
ZA (1) ZA200108610B (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10042137A1 (en) * 2000-08-28 2002-03-14 Florian Lang sgk2 and sgk3 as diagnostic and therapeutic targets
DE10113876A1 (en) * 2001-03-21 2002-09-26 Eberhard Karls Uni Medizinisch Quantitative diagnosis of genetically related hypertension, by correlating blood pressure with overexpression or modification of human sgk family proteins
WO2002087417A2 (en) * 2001-04-27 2002-11-07 Cold Spring Harbor Laboratory Alleviation of the memory deficits and memory components of psychiatric dysfunctions by altering atypical pkm activity
DE10149393A1 (en) * 2001-09-28 2003-04-24 Florian Lang Detecting the expression of serum and glucocorticoid-dependent kinase-1 (sgk1), for diagnosing coagulative diseases, diabetes, tumors, diabetes and autoimmune diseases, comprises using an antibody against sgk1
DE10225844A1 (en) * 2002-06-04 2003-12-18 Lang Florian sgk and nedd as diagnostic and therapeutic targets
DE10305212A1 (en) * 2003-02-07 2004-08-19 Florian Prof. Dr.med. Lang Use of the sgk gene family for the diagnosis and therapy of cataracts and glaucoma
KR20110005747A (en) * 2003-03-03 2011-01-18 플로리안 랑 Sgk1 as diagnostic and therapeutic target
WO2004084889A1 (en) * 2003-03-28 2004-10-07 Pfizer Inc. Use of protein kinase c inhibitor for suppressing sustained slow postsynaptic excitation (sspe) of enteric neurons
DE10346913A1 (en) 2003-10-09 2005-05-04 Merck Patent Gmbh acylhydrazone
WO2005084702A1 (en) * 2004-03-02 2005-09-15 Hokkaido Technology Licensing Office Co., Ltd. Agent for preventing and treating organ fibrosis
JP2007529423A (en) * 2004-03-11 2007-10-25 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング Methods for modulating glutamate receptors for the treatment of neuropsychiatric disorders, including the use of modulators of serum and glucocorticoid-inducible kinases
KR20070015149A (en) * 2004-03-11 2007-02-01 메르크 파텐트 게엠베하 Methods for interfering with fibrosis
US20090136920A1 (en) * 2004-04-30 2009-05-28 Stefan Golz Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase 1 (sgk1)
WO2005118832A2 (en) * 2004-06-01 2005-12-15 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase-like protein (sgkl)
DE102004030987A1 (en) * 2004-06-26 2006-01-12 Merck Patent Gmbh Ortho-substituted (3-hydroxyphenyl) -acetic acid benzylidene hydrazides
MX2007001155A (en) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Methods, systems, and computer program products for providing presence gateway functionality in a telecommunications network.
DE102005001053A1 (en) * 2005-01-07 2006-07-20 Merck Patent Gmbh Square acid derivatives
DE102005015255A1 (en) 2005-04-04 2006-10-05 Merck Patent Gmbh New acylhydrazide compounds are signal transduction kinase inhibitor, useful for treating and/or preventing diseases, e.g. diabetes, adiposity, metabolic syndrome, cancer and tumor cells
DE102005035742A1 (en) * 2005-07-29 2007-02-01 Merck Patent Gmbh New cyclobut-3-ene-1,2-dione derivatives are kinase inhibitors useful for treating e.g. cancer, hypertension, diabetes, glaucoma and bacterial infections
DE102005039541A1 (en) * 2005-08-22 2007-03-22 Merck Patent Gmbh 3-oxo-indazol-square acid derivatives
DE102007002717A1 (en) 2007-01-18 2008-07-24 Merck Patent Gmbh Heterocyclic indazole derivatives
DE102007022565A1 (en) 2007-05-14 2008-11-20 Merck Patent Gmbh Heterocyclic indazole derivatives
EP2014651A1 (en) * 2007-07-12 2009-01-14 Exonhit Therapeutics SA Compounds and methods for modulating Rho GTPases
DE102008010362A1 (en) * 2008-02-18 2009-08-20 Florian Prof. Dr. Lang Sgk1 as a therapeutic and diagnostic target for viral diseases
DE102008010363A1 (en) 2008-02-18 2009-08-20 Lang, Florian, Prof. Dr.med. Sgk1 as a therapeutic and diagnostic target for carcinomatous diseases
DE102008010361A1 (en) 2008-02-18 2009-08-20 Merck Patent Gmbh sgk1 inhibitors for the prophylaxis and / or therapy of viral diseases and / or carcinomas
DE102008029072A1 (en) * 2008-06-10 2009-12-17 Lang, Florian, Prof. Dr.med. Substance, which inhibits serum and glucocorticoid dependent kinase 3, useful for the prophylaxis and/or treatment or diagnosis of age-related diseases e.g. arteriosclerosis, skin atrophy, myasthenia, infertility, stroke and kyphosis
DE102008038221A1 (en) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-azaindole derivatives
DE102008038222A1 (en) 2008-08-18 2010-02-25 Merck Patent Gmbh Indazol-5-carboxylic acid derivatives
DE102008038220A1 (en) 2008-08-18 2010-02-25 Merck Patent Gmbh oxadiazole
DE102008059133A1 (en) 2008-11-26 2010-05-27 Merck Patent Gmbh Difluorophenyl diacylhydrazide derivatives
WO2012064981A2 (en) * 2010-11-10 2012-05-18 National Jewish Health Methods to test allergic conditions
CN107875153A (en) * 2017-11-16 2018-04-06 上海壹志医药科技有限公司 The medicinal usage of Des-N-methylchelerythrine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373501A (en) * 1976-12-11 1978-06-30 Kitasato Inst Novel antibiotics amm2282 and process for preparing same
US5242397A (en) * 1989-06-20 1993-09-07 Cedars-Sinai Medical Center Catheter device and method of use for intramural delivery of protein kinase C and tyrosine protein kinase inhibitors to prevent restenosis after balloon angioplasty
US5137912A (en) * 1991-01-28 1992-08-11 National Science Council Of Republic Of China Chelerythrine inhibits platelet aggregation--a potential anti-aggregation drug
GB9325395D0 (en) * 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
US5874464A (en) * 1995-01-13 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Conformationally constrained diacylglycerol analogues
WO1997007081A2 (en) * 1995-08-11 1997-02-27 Yale University Glycosylated indolocarbazole synthesis
HUP9901621A3 (en) * 1996-05-30 2002-01-28 Aventis Pharmaceuticals Inc Br Protein kinase c inhibitory activity alkyloxyamino substituted fluorenone derivatives, use thereof, intermediates and preparation of the latters, pharmaceutical compositions containing these compounds
EP0887081B1 (en) * 1997-06-27 2003-04-23 Smithkline Beecham Corporation Human serum glucocorticoid regulated kinase, a target for chronic renal disease and diabetic nephropathy
EP0889127A1 (en) * 1997-07-01 1999-01-07 Smithkline Beecham Corporation Serine/threonine protein kinase (H-SGK2)
CO4940430A1 (en) * 1997-07-07 2000-07-24 Novartis Ag POLYCLIC COMPOUNDS CONTAINING HYDROGENATED STAUROSPORIN WITH CONVENIENT PHARMACOLOGICAL PROPERTIES AND AN INHIBITING EFFECT ON THE GROWTH OF TUMOR CELLS

Also Published As

Publication number Publication date
NO20015054D0 (en) 2001-10-17
PL198427B1 (en) 2008-06-30
UA79066C2 (en) 2007-05-25
RU2288718C9 (en) 2008-04-27
SK14972001A3 (en) 2002-06-04
WO2000062781A1 (en) 2000-10-26
JP2002542196A (en) 2002-12-10
EP1171131A1 (en) 2002-01-16
DE19917990A1 (en) 2000-11-02
CZ20013778A3 (en) 2002-06-12
CN1351496A (en) 2002-05-29
AU779941B2 (en) 2005-02-17
MXPA01010588A (en) 2004-09-06
HUP0200819A3 (en) 2009-08-28
CA2369078A1 (en) 2000-10-26
KR20020012172A (en) 2002-02-15
AU4297200A (en) 2000-11-02
NO20015054L (en) 2001-12-14
HUP0200819A2 (en) 2002-07-29
BR0009914A (en) 2002-01-08
KR100718900B1 (en) 2007-05-17
RU2288718C2 (en) 2006-12-10
PL352547A1 (en) 2003-08-25

Similar Documents

Publication Publication Date Title
AU779941B2 (en) Medicaments containing inhibitors of cell-volume regulated human kinase h-sgk
EP3389725B1 (en) Compositions and methods for treatment of central nervous system diseases
Kiedrowski et al. Glutamate impairs neuronal calcium extrusion while reducing sodium gradient
Lanoue et al. Limb, genital, CNS, and facial malformations result from gene/environment‐induced cholesterol deficiency: further evidence for a link to sonic hedgehog
Goldhaber et al. Effects of TNF-alpha on [Ca2+] i and contractility in isolated adult rabbit ventricular myocytes
US6262116B1 (en) Transcription therapy for cancers
US20040082498A1 (en) Use of geldanamycin and related compounds for prophylaxis or treatment of fibrogenic disorders
US5434086A (en) Method of testing potential cystic fibrosis treating compounds using cells in culture
US20050064501A1 (en) Medicaments comprising inhibitors of the cell volume-regulated human kinase h-sgk
Yu et al. Deficiency of CC chemokine ligand 2 and decay-accelerating factor causes retinal degeneration in mice
US5888982A (en) Regulation of vascular smooth muscle cell heme oxygenase-1
Zhu et al. Progranulin deficiency leads to enhanced age-related cardiac hypertrophy through complement C1q-induced β-catenin activation
Maione et al. Ca2+ dysregulation in cardiac stromal cells sustains fibro-adipose remodeling in Arrhythmogenic Cardiomyopathy and can be modulated by flecainide
Focchi et al. ATM rules neurodevelopment and glutamatergic transmission in the hippocampus but not in the cortex
Nicolas et al. A postzygotic de novo NCDN mutation identified in a sporadic FTLD patient results in neurochondrin haploinsufficiency and altered FUS granule dynamics
Masuda et al. The transcription factor GTF2IRD1 regulates the topology and function of photoreceptors by modulating photoreceptor gene expression across the retina
US20090305225A1 (en) Inhibition of Creatine Uptake to Promote Weight Loss
US20040162257A1 (en) Antisense oligonucleotides capable of inhibiting the formation of capillary tubes by endothelial cells
WO2001017514A1 (en) Modulation of gene expression by modulating histone acetylation
Toutenhoofd et al. Regulation of calmodulin mRNAs in differentiating human IMR-32 neuroblastoma cells
US20240216320A1 (en) Compositions and methods for treating sickle cell disease
US20210145783A1 (en) Compositions and Methods for Treating Sickle Cell Disease
Lin et al. Chaperone-mediated autophagy is an overlooked pathway for mutant α1-antitrypsin Z degradation
WO1993007265A1 (en) Treatment of cystic fibrosis
US20210236438A1 (en) Compounds and methods for the treatment of autism spectrum disorder and other neurological or psychiatric disorders